https://www.selleckchem.com/products/cc-99677.html
8%) developed anti-drug antibody after administration. Conclusions Our study confirmed the PK similarity between BAT2506 and golimumab, and showed good tolerance of BAT2506 in healthy subjects. There were no differences in safety and immunogenicity between the two drugs. Therefore, BAT2506 meets the criteria for biosimilarity to golimumab. Trial registration The trial is registered at ClinicalTrials.gov (CT.gov identifier NCT04152759).Although used by resistance-trained individuals, it is unknown if increasing muscle strength prior to
Like
Comment
Share
